ChronoScale completes sale of Ekso Bionics unit and expands AI infrastructure contracts
ChronoScale Holdings completed the sale of its Ekso Bionics subsidiary on September 30, 2026, and said it will focus on its AI infrastructure business. On October 1, 2026, it also announced an expanded agreement with an existing AI infrastructure customer and a new customer agreement, which together with existing contracts provide for $1 billion in annualized revenue run rate by calendar Q3 2027. The filing does not disclose the sale price or the company's profit results, and the revenue run-rate is a non-GAAP measure subject to deployment and financing risks.
Key points
- Sale of Ekso Bionics, Inc., a wholly owned subsidiary, completed September 30, 2026; the filing does not state the sale price
- Expanded AI infrastructure customer agreement and new customer agreement, announced October 1, 2026, with combined contracts targeting $1 billion annualized revenue run rate by calendar Q3 2027
- Chief Operating Officer of Ekso, Jason C. Jones, terminated effective September 30, 2026, with severance of $243,750 plus up to nine months of COBRA premiums
- Series B Convertible Preferred Stock designation withdrawn September 29, 2026; no preferred shares were outstanding
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.